Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Plos One|February 27, 2019
Molecular analysis of small tissue samples obtained via transbronchial lung biopsy using radial probe endobronchial ultrasoundInsu Kim, Jung Seop Eom, Ah Rong Kim, et al.
Medicine|April 5, 2019
Reliability of PD-L1 assays using small tissue samples compared with surgical specimensInsu Kim, Ahrong Kim, Chang Hun Lee, et al.
Biosensors & Bioelectronics|February 6, 2023
Caco-2 cell-derived biomimetic electrochemical biosensor for cholera toxin detectionYonghwan Kim, Dongtak Lee, Youngjun Seo, et al.
Thoracic Cancer|May 21, 2025
Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR-Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort StudyMi-Hyun Kim, Min Ki Lee, Ji Eun Park, et al.
BMC Pulmonary Medicine|August 15, 2018
Radial probe endobronchial ultrasound using a guide sheath for peripheral lung lesions in beginnersJung Seop Eom, Jeong Ha Mok, Insu Kim, et al.
Translational Lung Cancer Research|May 19, 2025
Factors predicting early recurrence in patients with unresectable stage III non-small cell lung cancer on durvalumab consolidation after chemoradiotherapyJi Eun Park, Chanmi Kim, Sun Ha Choi, et al.
Translational Lung Cancer Research|October 24, 2025
Adjuvant chemotherapy before osimertinib in EGFR-mutated stage IB lung adenocarcinoma: a clinical dilemmaSun Hyo Park, Jin Han Park, Tae Hun Kim, et al.
Clinical Lung Cancer|March 19, 2024
Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter StudyJi Eun Park, Kyung Soo Hong, Sun Ha Choi, et al.
Clinical Lung Cancer|March 29, 2025
Longitudinal Analysis of Recurrence and Risk Factors of Early-Stage Resected Adenocarcinoma With Common EGFR Mutations: A Multicenter Retrospective Cohort Study in South KoreaJune Hong Ahn, Sun Ha Choi, Sun Hyo Park, et al.
Anticancer Research|September 30, 2024
PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLCInsu Kim, Sun Ha Choi, Shin Yup Lee, et al.
Pageof 7